Danielle van Manen
Overview
Explore the profile of Danielle van Manen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
1583
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Koornneef A, Vanshylla K, Hardenberg G, Rutten L, Strokappe N, Tolboom J, et al.
Nat Commun
. 2024 Apr;
15(1):3128.
PMID: 38605096
One of the strategies towards an effective HIV-1 vaccine is to elicit broadly neutralizing antibody responses that target the high HIV-1 Env diversity. Here, we present an HIV-1 vaccine candidate...
2.
Rutten L, Swart M, Koornneef A, Bouchier P, Blokland S, Sadi A, et al.
Sci Rep
. 2024 Mar;
14(1):5735.
PMID: 38459086
The spike protein (S) of SARS-CoV-2 induces neutralizing antibodies and is the key component of current COVID-19 vaccines. The most efficacious COVID-19 vaccines are genetically-encoded spikes with a double proline...
3.
van der Neut Kolfschoten M, Inganas H, Perez-Peinado C, Calado da Silva Freire J, Melchers J, van Dijk N, et al.
J Thromb Haemost
. 2023 Dec;
22(4):1046-1055.
PMID: 38159648
Background: COVID-19 vaccines have been widely used to control the SARS-CoV-2 pandemic. In individuals receiving replication-incompetent, adenovirus vector-based COVID-19 vaccines (eg, ChAdOx1 nCoV-19 [AstraZeneca] or Ad26.COV2.S [Johnson & Johnson/Janssen] vaccines),...
4.
Mercado N, Zahn R, Wegmann F, Loos C, Chandrashekar A, Yu J, et al.
Nature
. 2021 Jan;
590(7844):E25.
PMID: 33469218
No abstract available.
5.
Bos R, Rutten L, van der Lubbe J, Bakkers M, Hardenberg G, Wegmann F, et al.
NPJ Vaccines
. 2020 Oct;
5:91.
PMID: 33083026
Development of effective preventative interventions against SARS-CoV-2, the etiologic agent of COVID-19 is urgently needed. The viral surface spike (S) protein of SARS-CoV-2 is a key target for prophylactic measures...
6.
Mercado N, Zahn R, Wegmann F, Loos C, Chandrashekar A, Yu J, et al.
Nature
. 2020 Jul;
586(7830):583-588.
PMID: 32731257
A safe and effective vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may be required to end the coronavirus disease 2019 (COVID-19) pandemic. For global deployment and pandemic control,...
7.
Barouch D, Tomaka F, Wegmann F, Stieh D, Alter G, Robb M, et al.
Lancet
. 2018 Jul;
392(10143):232-243.
PMID: 30047376
Background: More than 1·8 million new cases of HIV-1 infection were diagnosed worldwide in 2016. No licensed prophylactic HIV-1 vaccine exists. A major limitation to date has been the lack...
8.
Kang Z, Bricault C, Borducchi E, Stephenson K, Seaman M, Pau M, et al.
J Virol
. 2018 May;
92(15).
PMID: 29793950
Vaccine-elicited immunoglobulin G (IgG) has been shown to be important for protection against simian-human immunodeficiency virus (SHIV) infection in rhesus monkeys. However, it remains unclear whether vaccine-elicited IgA responses are...
9.
Rutten L, Lai Y, Blokland S, Truan D, Bisschop I, Strokappe N, et al.
Cell Rep
. 2018 Apr;
23(2):584-595.
PMID: 29642014
The heavily glycosylated native-like envelope (Env) trimer of HIV-1 is expected to have low immunogenicity, whereas misfolded forms are often highly immunogenic. High-quality correctly folded Envs may therefore be critical...
10.
McLaren P, Coulonges C, Bartha I, Lenz T, Deutsch A, Bashirova A, et al.
Proc Natl Acad Sci U S A
. 2015 Nov;
112(47):14658-63.
PMID: 26553974
Previous genome-wide association studies (GWAS) of HIV-1-infected populations have been underpowered to detect common variants with moderate impact on disease outcome and have not assessed the phenotypic variance explained by...